The U.S. Food and Drug Administration (FDA), an ICCVAM member agency, is coordinating an upcoming public workshop at its White Oak campus in Silver Spring, Maryland. The goal of the workshop is to review test methods that are likely to predict clinical thrombogenic potential of blood-contacting medical devices. Information about the workshop will be provided at a later date. Prior to the workshop, input is requested on current practices used for in vitro and in vivo thrombogenicity testing.